Paper Details

  1. Home
  2. Paper Details

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring <i>FGF</i>/<i>FGFR</i> Aberrations: A Phase I Dose-Expansion Study.

Author: ArkenauHendrik-Tobias, BahledaRastislav, BenhadjiKarim A, BridgewaterJohn, GoyalLipika, HeYaohua, HierroCinta, JavleMilind, KelleyRobin Kate, Meric-BernstamFunda, ParkJoon Oh, SansonMarc, TranBen

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Futibatinib is a highly selective, irreversible FGFR1-4 inhibitor that showed an objective response rate (ORR) of 13.7% in a phase I dose-expansion trial of 197 patients with advanced solid tumors. The drug was effective across a range of tumors, including cholangiocarcinoma, gastric, urothelial, central nervous system, head and neck, and breast cancer, with both known and previously uncharacterized FGFR1-3 aberrations. The highest activity was seen in FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (ORR, 25.4%). Some patients with acquired resistance to a prior FGFR inhibitor also experienced responses with futibatinib. The most common treatment-emergent adverse events were hyperphosphatemia (81.2%), diarrhea (33.5%), and nausea (30.4%).
Paper Details　
Original Abstract of the Article :
Futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, was evaluated in a large multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid tumors. Futibatinib demonstrated an objective response rate (ORR) of 13.7%, with responses in a broad spectrum of tumor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762334/

データ提供：米国国立医学図書館（NLM）

Futibatinib: A New Weapon in the Fight Against Solid Tumors

The world of cancer research is an endless desert, with researchers constantly searching for new weapons to combat this formidable adversary. This study investigates the potential of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor, as a powerful weapon in the fight against advanced solid tumors. The research involved a phase I dose-expansion trial, a crucial step in evaluating a drug's safety and effectiveness. The results reveal that futibatinib demonstrated a significant objective response rate (ORR), particularly in patients with FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma. This finding suggests that futibatinib could be a potent weapon against specific types of tumors, like targeting a specific oasis in the vast desert landscape.

A New Oasis in the Desert of Cancer

This research provides a ray of hope for patients with FGFR-aberrant tumors, offering the potential for targeted therapy. The study's findings, a testament to the power of genomically selected trials, highlight the importance of personalized medicine, like tailoring a camel caravan's route to avoid dangerous regions. This research offers a new weapon in the fight against cancer and points towards the importance of continued research into targeted therapies.

A Hopeful Glimpse in the Fight Against Cancer

This research underscores the potential of futibatinib as a promising treatment option for patients with FGFR-aberrant tumors. The results demonstrate that targeted therapies can be effective in combating specific types of cancer, like utilizing a specific weapon for a specific threat. While further research is needed to fully understand the potential of futibatinib, this study offers a glimmer of hope in the fight against cancer, like finding a source of water in a seemingly barren desert.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the fight against cancer. Futibatinib demonstrates promise as a targeted therapy, providing a potential oasis in the vast desert of cancer research. This is a critical step towards developing personalized treatments that offer hope for a cure.

Date :
  1. Date Completed 2022-03-14
  2. Date Revised 2023-04-21
Further Info :

Pubmed ID

34551969

DOI: Digital Object Identifier

PMC9762334

Related Literature

Article Analysis
・Effects of futibatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.